Taipei, Taiwan, 21 January 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced the advancement of its Vietnam drug portfolio acquisition. Lotus had entered into an asset purchase agreement to acquire trademarks, market authorisations, and the assignment of manufacturing and supply agreements related to a portfolio of five drug products in Vietnam (as announced on 18 June 2025). To date, the closing conditions for Betahema, Folinato, Carmotop and Espacox have been fulfilled, and sales are expected to commence in Q1 2026.
The portfolio of five drug products covers a wide range of therapeutic areas, including hematology, cardiovascular disease, oncology, and anti-inflammatory treatments. Sales of this portfolio in Vietnam were approximately US$8 million in 2024 and achieved a compound annual growth rate (CAGR) of 22% from 2022 to 2024, underscoring their strong commercial potential in the local market.
Petar Vazharov, Chief Executive Officer of Lotus, commented, "We are excited to bring this portfolio of high-quality and affordable medicines to Southeast Asia. Looking ahead, we will continue work towards further expanding our product portfolio to broaden patient access, in line with our longstanding commitment to delivering high-quality and accessible medicines to those in need.”
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com